|
1
|
Murati A, Brecqueville M, Devillier R,
Mozziconacci MJ, Gelsi-Boyer V and Birnbaum D: Myeloid
malignancies: Mutations, models and management. BMC Cancer.
12:3042012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shih AH, Abdel-Wahab O, Patel JP and
Levine RL: The role of mutations in epigenetic regulators in
myeloid malignancies. Nat Rev Cancer. 12:599–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McPherson S, McMullin MF and Mills K:
Epigenetics in myeloproliferative neoplasms. J Cell Mol Med.
21:1660–1667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piazza R, Valletta S, Winkelmann N,
Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni
C, Papaemmanuil E, et al: Recurrent SETBP1 mutations in atypical
chronic myeloid leukemia. Nat Genet. 45:18–24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cristóbal I, Blanco FJ, Garcia-Orti L,
Marcotegui N, Vicente C, Rifon J, Novo FJ, Bandres E, Calasanz MJ,
Bernabeu C and Odero MD: SETBP1 overexpression is a novel
leukemogenic mechanism that predicts adverse outcome in elderly
patients with acute myeloid leukemia. Blood. 115:615–625. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oakley K, Han Y, Vishwakarma BA, Chu S,
Bhatia R, Gudmundsson KO, Keller J, Chen X, Vasko V, Jenkins NA, et
al: Setbp1 promotes the self-renewal of murine myeloid progenitors
via activation of Hoxa9 and Hoxa10. Blood. 119:6099–6108. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trimarchi T, Ntziachristos P and Aifantis
I: A new player SETs in myeloid malignancy. Nat Genet. 45:846–847.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akiki S, Dyer SA, Grimwade D, Ivey A,
Abou-Zeid N, Borrow J, Jeffries S, Caddick J, Newell H, Begum S, et
al: NUP98-NSD1 fusion in association with FLT3-ITD mutation
identifies a prognostically relevant subgroup of pediatric acute
myeloid leukemia patients suitable for monitoring by real time
quantitative PCR. Genes Chromosomes Cancer. 52:1053–1064. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hollink IH, van den Heuvel-Eibrink MM,
Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen
JF, Beverloo HB, Sonneveld E, Kaspers GJ, et al: NUP98/NSD1
characterizes a novel poor prognostic group in acute myeloid
leukemia with a distinct HOX gene expression pattern. Blood.
118:3645–3656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiba N, Ichikawa H, Taki T, Park MJ, Jo
A, Mitani S, Kobayashi T, Shimada A, Sotomatsu M, Arakawa H, et al:
NUP98-NSD1 gene fusion and its related gene expression signature
are strongly associated with a poor prognosis in pediatric acute
myeloid leukemia. Genes Chromosomes Cancer. 52:683–693.
2013.PubMed/NCBI
|
|
11
|
Rosati R, La Starza R, Veronese A, Aventin
A, Schwienbacher C, Vallespi T, Negrini M, Martelli MF and Mecucci
C: NUP98 is fused to the NSD3 gene in acute myeloid leukemia
associated with t(8;11)(p11.2;p15). Blood. 99:3857–3860. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taketani T, Taki T, Nakamura H, Taniwaki
M, Masuda J and Hayashi Y: NUP98-NSD3 fusion gene in
radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15)
and expression pattern of NSD family genes. Cancer Genet Cytogenet.
190:108–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chesi M, Nardini E, Lim RS, Smith KD,
Kuehl WM and Bergsagel PL: The t(4;14) translocation in myeloma
dysregulates both FGFR3 and a novel gene, MMSET, resulting in
IgH/MMSET hybrid transcripts. Blood. 92:3025–3034. 1998.PubMed/NCBI
|
|
14
|
Jaffe JD, Wang Y, Chan HM, Zhang J,
Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, et
al: Global chromatin profiling reveals NSD2 mutations in pediatric
acute lymphoblastic leukemia. Nat Genet. 45:1386–1391. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gelsi-Boyer V, Trouplin V, Adélaïde J,
Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M,
Sainty D, et al: Mutations of polycomb-associated gene ASXL1 in
myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br
J Haematol. 6:788–800. 2009. View Article : Google Scholar
|
|
16
|
Abdel-Wahab O, Tefferi A and Levine RL:
Role of TET2 and ASXL1 mutations in the pathogenesis of
myeloproliferative neoplasms. Hematol Oncol Clin North Am.
5:1053–1064. 2012. View Article : Google Scholar
|
|
17
|
Makishima H, Yoshida K, Nguyen N,
Przychodzen B, Sanada M, Okuno Y, Ng KP, Gudmundsson KO,
Vishwakarma BA, Jerez A, et al: Somatic SETBP1 mutations in myeloid
malignancies. Nat Genet. 45:942–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Makishima H: Somatic SETBP1 mutations in
myeloid neoplasms. Int J Hematol. 105:732–742. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saeidi K: Myeloproliferative neoplasms:
Current molecular biology and genetics. Crit Rev Oncol Hematol.
98:375–389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tefferi A, Pardanani A, Lim KH,
Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S,
Mullally A, et al: TET2 mutations and their clinical correlates in
polycythemia vera, essential thrombocythemia and myelofibrosis.
Leukemia. 23:905–911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carvalho E, Honjo R, Magalhães M, Yamamoto
G, Rocha K, Naslavsky M, Zatz M, Passos-Bueno MR, Kim C and Bertola
D: Schinzel-Giedion syndrome in two Brazilian patients: Report of a
novel mutation in SETBP1 and literature review of the clinical
features. Am J Med Genet 167A. 1039–1046. 2015. View Article : Google Scholar
|
|
22
|
Acuna-Hidalgo R, Deriziotis P, Steehouwer
M, Gilissen C, Graham SA, van Dam S, Hoover-Fong J, Telegrafi AB,
Destree A, Smigiel R, et al: Overlapping SETBP1 gain-of-function
mutations in Schinzel-Giedion syndrome and hematologic
malignancies. PLoS Genet. 13:e10066832017. View Article : Google Scholar : PubMed/NCBI
|
